Brief: Nicox Granted Patent For NCX 470, Extending Exclusivity In Europe To 2039

Nicox SA

29/10/2020 08:23

Oct 29 (Reuters) - NICOX SA  NCOX.PA :
    * NICOX GRANTED NEW PATENT FOR NCX 470, EXTENDING
EXCLUSIVITY IN
EUROPE TO 2039
    * A SECOND PHASE 3 TRIAL, DENALI, IS EXPECTED TO START BY
END OF
2020
    * NCX 470 IS CURRENTLY BEING EVALUATED IN MONT BLANC PHASE 3
CLINICAL TRIAL WITH TOP-LINE RESULTS CURRENTLY EXPECTED IN Q4
2021
    * EQUIVALENT U.S. PATENT HAS ALREADY BEEN GRANTED, AND NCX
470 IS
ALSO COVERED BY GRANTED COMPOSITION OF MATTER PATENTS
    * DENALI TRIAL IS JOINTLY FUNDED BY NICOX AND OCUMENSION

Source text for Eikon:  ID:nGNE6dfhzQ 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))